The biotechnology company ended development of a potential treatment for a genetic condition that targets the liver.
Investors remained cautious about the beaten down restaurant and arcade owner, despite reporting surprisingly good first-quarter earnings.
The biotechnology company's potential eczema cream ruxolitinib faces a delayed regulatory review.
The biotechnology company gave investors an encouraging development update for a potential diabetes treatment.
The chipmaker, which agreed to a buyout from South Dearborn, received a bigger offer from
The cruise line operator said two guests sharing a stateroom onboard its Celebrity Millennium tested positive for COVID-19.
The maker of analysis and processing equipment for semiconductor companies is reportedly seeking to buy
The maker of hard drives for businesses and personal computers gave investors an encouraging update during a business conference.
Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source